In chronic HF, empagliflozin reduced a composite of CV death or HF hospitalization across kidney risk categories
- PMID: 37665991
- DOI: 10.7326/J23-0065
In chronic HF, empagliflozin reduced a composite of CV death or HF hospitalization across kidney risk categories
Abstract
Butler J, Packer M, Siddiqi TJ, et al. Efficacy of empagliflozin in patients with heart failure across kidney risk categories. J Am Coll Cardiol. 2023;81:1902-1914. 37164523.
Conflict of interest statement
Comment on
-
Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories.J Am Coll Cardiol. 2023 May 16;81(19):1902-1914. doi: 10.1016/j.jacc.2023.03.390. J Am Coll Cardiol. 2023. PMID: 37164523
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous